The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The 10-day moving average for APUS crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +121.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where APUS advanced for three days, in 44 of 49 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 31 of 35 cases where APUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
The 10-day RSI Indicator for APUS moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 7 similar instances where the indicator moved out of overbought territory. In 5 of the 7 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on APUS as a result. In 24 of 27 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for APUS turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 13 similar instances when the indicator turned negative. In 13 of the 13 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
APUS moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
APUS broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.046) is normal, around the industry mean (10.407). P/E Ratio (-0.090) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. APUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
PAHC saw its Momentum Indicator move above the 0 level on September 29, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 65 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.
The Moving Average Convergence Divergence (MACD) for PAHC just turned positive on October 01, 2026. Looking at past instances where PAHC's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
PAHC moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PAHC crossed bullishly above the 50-day moving average on October 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +2.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAHC advanced for three days, in 214 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 171 of 247 cases where PAHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
PAHC broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. PAHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.193) is normal, around the industry mean (10.407). P/E Ratio (16.183) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.350) is also within normal values, averaging (2.152). Dividend Yield (0.012) settles around the average of (0.037) among similar stocks. P/S Ratio (0.953) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
PAHC | ||
|---|---|---|
OUTLOOK RATING 1..100 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 60 | |
SMR RATING 1..100 | 34 | |
PRICE GROWTH RATING 1..100 | 47 | |
P/E GROWTH RATING 1..100 | 90 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| APUS | PAHC | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | N/A |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 73% |
| Momentum ODDS (%) | 1 day ago 89% | 1 day ago 76% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 76% |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 75% |
| Advances ODDS (%) | 17 days ago 90% | 1 day ago 75% |
| Declines ODDS (%) | 1 day ago 90% | 10 days ago 74% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 68% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 69% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APUS’s FA Score shows that 2 FA rating(s) are green while PAHC’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APUS’s TA Score shows that 4 TA indicator(s) are bullish while PAHC’s TA Score has 5 bullish TA indicator(s).
APUS (@Pharmaceuticals: Generic) experienced а -29.04% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was +3.48% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
APUS is expected to report earnings on Nov 11, 2026.
PAHC is expected to report earnings on Nov 04, 2026.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor indicates that over the last year, APUS has been loosely correlated with DERM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if APUS jumps, then DERM could also see price increases.
| Ticker / NAME | Correlation To APUS | 1D Price Change % | ||
|---|---|---|---|---|
| APUS | 100% | -2.77% | ||
| DERM - APUS | 49% Loosely correlated | +6.04% | ||
| SNOA - APUS | 41% Loosely correlated | N/A | ||
| ACB - APUS | 24% Poorly correlated | +0.25% | ||
| PAHC - APUS | 21% Poorly correlated | +1.43% | ||
| TRLV - APUS | 11% Poorly correlated | -0.73% | ||
More | ||||
A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with ZTS. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then ZTS could also see price increases.
| Ticker / NAME | Correlation To PAHC | 1D Price Change % | ||
|---|---|---|---|---|
| PAHC | 100% | +1.43% | ||
| ZTS - PAHC | 61% Loosely correlated | +2.99% | ||
| ELAN - PAHC | 47% Loosely correlated | +0.62% | ||
| VTRS - PAHC | 29% Poorly correlated | +0.16% | ||
| LFCR - PAHC | 27% Poorly correlated | N/A | ||
| AKBA - PAHC | 26% Poorly correlated | -3.95% | ||
More | ||||